• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
XL-765

XL-765

Product ID X4424
Cas No. 934493-76-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $147.20 Please Inquire
5 mg $249.80 Please Inquire
10 mg $405.20 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

XL-765 is an inhibitor of PI3K and mTOR that displays anticancer chemotherapeutic and anti-angiogenic activities; it is currently in clinical trials as a potential treatment for lymphomas and solid tumors. XL-765 inhibits cell proliferation, tumor growth, and angiogenesis in cellular and animal models of cancers.

Product Info

Cas No.

934493-76-2

Purity

≥98%

Formula

C13H14N6O

Formula Wt.

270.29

IUPAC Name

2-Amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)-one

Synonym

XL765, Voxtalisib, SAR245409

Solubility

DMSO 12 mg/mL (20.01 mM) Water Insoluble Ethanol Insoluble

Appearance

Light yellow powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

X4424 MSDS PDF

Info Sheet

X4424 Info Sheet PDF

References

Papadopoulos KP, Egile C, Ruiz-Soto R, et al. Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. Leuk Lymphoma. 2014 Nov 19:1-8. [Epub ahead of print] PMID: 25300944.

Yu P, Laird AD, Du X, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014 May;13(5):1078-91. PMID: 24634413.

Papadopoulos KP, Tabernero J, Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2014 May 1;20(9):2445-56. PMID: 24583798.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C2916

    Chenodeoxycholic Acid

    Endogenous bile acid; FXR agonist.

    ≥98%
  • L0077

    Latrunculin B

    Thiazolidinone macrolide found in the Red Sea s...

    ≥98%
  • B6800

    Bradykinin Triacetate

    Natriuretic, vasodilatory peptide; B1/2 agonist...

    ≥95%
  • D3420

    4-(3,4-Difluorobenzo)curcumin

    Curcumin derivative.

    ≥95%
  • M1745

    Melatonin

    Endogenous hormone involved in circadian rhythm...

    ≥98%
  • S8151

    Sumatriptan Succinate

    Tryptamine; 5-HT1B/1D agonist, TRPV1 antagonist...

    ≥99%
  • L0107

    Lactacystin

    Found in Streptomyces; proteasome inhibitor.

    ≥98%
  • B0397

    BAY80-6946 Hydrochloride

    pan-PI3K inhibitor

    ≥98%
  • E7376

    Estradiol

    Endogenous steroid hormone, involved in regulat...

    ≥97%
  • M4004

    MK-2461

    MET, FGFR, PDGFR inhibitor.

    ≥99%
  • F4502

    Flavokawain A

    Chalcone kavalactone found in Piper methysticum...

    ≥98%
  • E6470

    Eprinomectin

    Semi-synthetic avermectin; GABA potentiator.

    ≥45%
  • L283720

    Losartan Carboxylic acid

    Active metabolite of losartan

    ≥ 99%
  • M2408

    MGCD-265 Analog

    MET inhibitor.

    ≥98%
  • S7970

    Strontium Ranelate

    Bone deterioration inhibitor, potential CaR ago...

    ≥98%
  • S6800

    SR1001

    RORα/γ inverse agonist.

    ≥99%
  • N0061

    D-Naproxen

    NSAID; COX-1/2 inhibitor.

    ≥99%
  • T0094

    2′,7-Bisacetyltaxol

    Taxane synthesis intermediate.

    ≥96%
  • D364086

    Decernotinib

    JAK3 inhibitor.

    ≥99%
  • D1757

    L-Deoxyalliin

    Organosulfur found in garlic.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only